News

Stock Movers: Circle Falls, Disney Climbs, Moderna Meets Flu Shot Goal
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine
RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...
Fierce Biotech15h
Moderna's mRNA flu vaccine beats approved competitor in latest phase 3 win, teeing up push to FDA
The latest phase 3 win is a boost for Moderna’s attempts to create a flu/COVID combination vaccine. The company withdrew a filing for FDA approval for its combo candidate last month while it waited ...
MarketWatch16h
Moderna Sees Positive Phase 3 Results for Seasonal Flu Vaccine
Moderna's messenger RNA flu vaccine candidate has shown has shown positive results in a late-stage trial. The biotechnology company said Monday its seasonal influenza vaccine candidate, mRNA-1010, ...
Investor's Business Daily on MSN13h
Did Down-And-Out Moderna Just Unlock The Key To Its Future Profitability?
Moderna stock veered higher Monday after its flu shot proved to be as effective as older technology in a final-phase study.
BioSpace23h
Moderna, Merck, UroGen, Score RSV and Cancer Nods in June
The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...
What is myocarditis? What to know about heart risk warning related to COVID-19 vaccines
The FDA has updated labels on the top two COVID-19 vaccines to warn of a rare heart side effect, mostly seen in young men.
StockStory.org on MSN4d
The Top 5 Analyst Questions From Moderna’s Q1 Earnings Call
Moderna’s first quarter results were met with a negative market reaction, as revenue fell short of Wall Street expectations ...